Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1557183 | 0.93 | MEN1 (0.39) | PPARGPPARA | |
| SCHEMBL1556876 | 0.85 | CASP2 (0.48) | PPARGPPARA | |
| SCHEMBL3248298 | 0.84 | — | — | |
| SCHEMBL10895511 | 0.83 | HSP90AA1 (0.55) | PPARGPPARA | |
| SCHEMBL10531381 | 0.83 | HSP90AA1 (0.55) | PPARGPPARA | |
| SCHEMBL1495189 | 0.83 | SLC6A5 (0.41) | PPARGPPARAEP300CNR1 | |
| SCHEMBL6529676 | 0.81 | HSP90AA1 (0.52) | CNR1 | |
| SCHEMBL1556426 | 0.80 | EP300 (0.42) | PPARGPPARAEP300 | |
| SCHEMBL1556006 | 0.78 | CASP2 (0.45) | PPARGPPARA | |
| SCHEMBL1458398 | 0.78 | HSP90AA1 (0.43) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7285572-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135572-A1 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1630157-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | PPARG 1041/4885PPARA 921/4885EP300 1799/4885 |
| US-20060135572-A1 | CaSR antagonist | CASR, CALCR, CALCRL | PPARG 1385/4885PPARA 1141/4885EP300 2054/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | PPARG 1041/4885PPARA 921/4885EP300 1799/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | PPARG 1041/4885PPARA 921/4885EP300 1799/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | PPARG 671/4885PPARA 738/4885EP300 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.